PL2379066T3 - Zastosowanie antagonistów opioidów do otrzymywania leku w leczeniu chorób zwyrodnieniowych siatkówki - Google Patents

Zastosowanie antagonistów opioidów do otrzymywania leku w leczeniu chorób zwyrodnieniowych siatkówki

Info

Publication number
PL2379066T3
PL2379066T3 PL08807092T PL08807092T PL2379066T3 PL 2379066 T3 PL2379066 T3 PL 2379066T3 PL 08807092 T PL08807092 T PL 08807092T PL 08807092 T PL08807092 T PL 08807092T PL 2379066 T3 PL2379066 T3 PL 2379066T3
Authority
PL
Poland
Prior art keywords
medicament
preparation
treatment
degenerative diseases
opioid antagonists
Prior art date
Application number
PL08807092T
Other languages
English (en)
Inventor
Ibrahim Mustafa Iskender Pisak
Mehmet Levent Selamoglu
Nevhiz Pak
Semra Bingol
Original Assignee
Imuneks Farma Ilac Sanayi Ve Ticaret A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imuneks Farma Ilac Sanayi Ve Ticaret A S filed Critical Imuneks Farma Ilac Sanayi Ve Ticaret A S
Publication of PL2379066T3 publication Critical patent/PL2379066T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
PL08807092T 2008-09-16 2008-09-16 Zastosowanie antagonistów opioidów do otrzymywania leku w leczeniu chorób zwyrodnieniowych siatkówki PL2379066T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08807092.5A EP2379066B1 (en) 2008-09-16 2008-09-16 Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases
PCT/IB2008/002412 WO2010032073A1 (en) 2008-09-16 2008-09-16 Use of opioid antagonists for the preparation of a medicament in the treatment of retinal degenerative diseases

Publications (1)

Publication Number Publication Date
PL2379066T3 true PL2379066T3 (pl) 2014-09-30

Family

ID=41138810

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08807092T PL2379066T3 (pl) 2008-09-16 2008-09-16 Zastosowanie antagonistów opioidów do otrzymywania leku w leczeniu chorób zwyrodnieniowych siatkówki

Country Status (10)

Country Link
US (1) US20110165232A1 (pl)
EP (1) EP2379066B1 (pl)
CY (1) CY1115269T1 (pl)
DK (1) DK2379066T3 (pl)
ES (1) ES2475199T3 (pl)
HR (1) HRP20140596T1 (pl)
PL (1) PL2379066T3 (pl)
PT (1) PT2379066E (pl)
SI (1) SI2379066T1 (pl)
WO (1) WO2010032073A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2482816B8 (en) * 2009-10-01 2016-12-14 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Topical compositions of naltrexone for treating skin conditions
TR201002473A2 (tr) 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
KR20130030261A (ko) 2010-05-10 2013-03-26 유로-셀티큐 에스.에이. 활성제-무함유 과립 및 그를 포함하는 정제의 제조
GB2492037A (en) 2010-05-10 2012-12-19 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
US20140213605A1 (en) * 2013-01-27 2014-07-31 Remedeye Inc. Methods for treating eye disorders using opioid receptor antagonists
CN112716955A (zh) 2013-11-13 2021-04-30 欧洲凯尔特公司 用于治疗疼痛和阿片样物质肠功能障碍综合征的氢吗啡酮和纳洛酮

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4416886A (en) * 1981-07-29 1983-11-22 Dermall Limited Method of treating pruritis and composition therefor
US4888346A (en) * 1986-10-07 1989-12-19 Bernard Bihari Method for the treatment of persons infected with HTLV-III (AIDS) virus
US5356900A (en) * 1986-10-07 1994-10-18 Bernard Bihari Method of treating chronic herpes virus infections using an opiate receptor antagonist
US4857533A (en) * 1988-12-15 1989-08-15 Baker Cummins Pharmaceuticals, Inc. Method of treatment for autoimmune diseases
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6384044B1 (en) 1999-11-29 2002-05-07 Bernard Bihari Method of treating cancer of the prostate
US20030072724A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition to treat hyperpigmentation of the skin
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
AU2001234730A1 (en) 2000-02-01 2001-08-14 Beth Israel Deaconess Medical Center Method for inhibiting complement activation
US20030191147A1 (en) * 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
US6821523B2 (en) * 2002-06-21 2004-11-23 Dermatrends, Inc. Topical administration of pharmacologically active bases in the treatment of warts
US20030235542A1 (en) * 2002-06-21 2003-12-25 Maibach Howard I. Topical administration of pharmacologically active bases for skin lightening
WO2004091593A2 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
US7375111B2 (en) * 2003-04-29 2008-05-20 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20060069086A1 (en) * 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2006131545A (ja) * 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
WO2006096626A2 (en) * 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8916195B2 (en) * 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US8829020B2 (en) * 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
EP2482816B8 (en) * 2009-10-01 2016-12-14 Imuneks Farma Ilaç Sanayi Ve Ticaret A.S. Topical compositions of naltrexone for treating skin conditions
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.

Also Published As

Publication number Publication date
HRP20140596T1 (hr) 2014-08-01
EP2379066A1 (en) 2011-10-26
ES2475199T3 (es) 2014-07-10
US20110165232A1 (en) 2011-07-07
EP2379066B1 (en) 2014-03-26
WO2010032073A1 (en) 2010-03-25
SI2379066T1 (sl) 2014-08-29
CY1115269T1 (el) 2017-01-04
DK2379066T3 (da) 2014-06-30
PT2379066E (pt) 2014-07-04

Similar Documents

Publication Publication Date Title
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
IL258356A (en) Use of synthetic retinal histology for the preparation of a medicament for the treatment or prevention of age-related retinal dysfunction or for improving rhodopsin ratio regeneration in humans
IL232251B (en) Pharmaceutical combination for use in the treatment of type 2 diabetes patients
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL221795B (en) Use of a pharmaceutical preparation of methylnaltrexone or a salt thereof for the preparation of a medicine for the treatment of side effects of treatment with opiates
IL211279A (en) Use of the tspan12 antagonist in the preparation of a blood vessel inhibition drug
IL221744A (en) Use of a combination of compounds to prepare a drug to treat Parkinson's disease
EP2265124A4 (en) AEROSOLISED LFA-1 ANTAGONISTS FOR THE USE IN THE LOCAL TREATMENT OF IMMUNE DISEASES
IL236360A0 (en) Inhalable medicine
ZA201304303B (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
IL218283A (en) Use of a mixture of factors for the preparation of drugs for the treatment of diseases of proliferation
IL210545A (en) Transplantation devices for use of octreotide transport and use of octreotide to create drugs
PL2379066T3 (pl) Zastosowanie antagonistów opioidów do otrzymywania leku w leczeniu chorób zwyrodnieniowych siatkówki
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
IL212966A (en) Pyrazole-1-yl-methyl-cyclohexyl-acetic acid compounds, pharmaceutical preparations containing them, use of pharmaceutical preparation compounds and compounds for use in treatment method
HK1158232A1 (en) Therapeutic use of specific ligand in msrv associated diseases msrv
PL3067353T3 (pl) Sposób wytwarzania soli solifenacyny i ich włączenie do farmaceutycznych postaci dawkowania
ZA200908962B (en) A liquid formulation for administering nicotine
IL218230B (en) Use of lapatinib or an acceptable pharmaceutical salt or preparation thereof for the preparation of a drug for the treatment of cancer
PT2603238E (pt) Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo
ZA201201028B (en) Fgf receptor-activating n-acyl octasaccharides,preparation thereof,and therapeutic use thereof
HRP20151393T8 (hr) UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE
HK1135019A1 (en) Use of l-carnitine for the preparation of a medicament in the form of eye- drops for treating corneal diseases l-
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders